Clinical Trial

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Name: A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer — clinical trial record (NCT06283121)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-02-22.

Trial Details

NCT Number	NCT06283121
Lead Sponsor	China Medical University, China Collaborators: Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Conditions	Gastric Cancer, Metastatic
Enrollment	30 participants
Start Date	2024-04-02
Primary Completion	2027-11-30 (estimated)
Study Completion	2027-11-30 (estimated)
Updated on ClinicalTrials.gov	2024-02-29